Bastiaan Sallevelt

97 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.3. Continued. STOPP Condition Clarity rating n=80 D7 to treat extra-pyramidal side-effects of neuroleptic medications 50% D11 with a known history of persistent bradycardia (< 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil 50% F2 for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 50% H6 for chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor e.g. allopurinol, febuxostat 50% I2 in those with symptomatic orthostatic hypotension or micturition syncope 50% J3 in diabetes mellitus with frequent hypoglycaemic episodes 50% L1 as first line therapy for mild pain 50% B1 for heart failure with normal systolic ventricular function 58% B2 with NYHA Class III or IV heart failure 58% B7 for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure 58% H3 for symptom relief of osteoarthritis pain where paracetamol has not been tried 58% H8 with concurrent corticosteroids without PPI prophylaxis 58% J2 in patients with heart failure 58% J6 in the absence of primary or secondary hypogonadism 58% B9 for treatment of hypertension with concurrent urinary incontinence 67% B12 without monitoring of serum potassium 67% C5 in patients with chronic atrial fibrillation 67% C8 for first deep venous thrombosis without continuing provoking risk factors (e.g. thrombophilia) for > 6 months, 67% C9 for first pulmonary embolus without continuing provoking risk factors (e.g. thrombophilia) for > 12 months 67% C10 in combination 67% C11 with concurrent antiplatelet agent(s) without PPI prophylaxis 67% F3 in patients with chronic constipation where non-constipating alternatives are available 67% G2 instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 67% H4 as monotherapy for rheumatoid arthrtitis 67% B8 with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 75% 2